Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989)

Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a globally recognized pharmaceutical company with extensive operations across Hong Kong, the United States, Europe, Mainland China, and in other international markets. The company boasts a diverse product portfolio that spans across various segments of the pharmaceutical industry, including Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), and Contract Development and Manufacturing Organization. Since its establishment in 1998 and subsequent name change from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017, the company has significantly expanded its reach and capabilities. It provides comprehensive pharmaceutical services ranging from research and development to manufacturing and quality management. Besides pharmaceuticals, Hepalink is also invested in property management, investment consulting, biopharmaceutical technology, and equity and venture investment activities, showcasing its versatility and dynamic approach to business. Headquartered in Shenzhen, the People's Republic of China, Hepalink continues to play an influential role in the global pharmaceutical industry.

Products and Services

Finished Dose Pharmaceutical Products: The company's range in this category prominently includes enoxaparin sodium injection, known for its effectiveness in preventing blood clots. These products are critical for use in various medical procedures and patient care protocols.

Active Pharmaceutical Ingredients (API): Hepalink specializes in the production of high-quality API products such as heparin sodium API and enoxaparin sodium API. These ingredients are essential for the pharmaceutical industry, serving as the foundational components for a myriad of drug formulations.

Other Products: The portfolio here encompasses pancreatin API, a vital digestion aid among other pharmaceutical necessities. This diversification underscores Hepalink's capacity to meet a wide range of healthcare needs.

Contract Development and Manufacturing Organization (CDMO): This segment reflects Hepalink's comprehensive service offerings, which include research and development, manufacturing, quality management, and program management services. The company stands out for its ability to assist other pharmaceutical businesses in developing and manufacturing their products, ensuring high quality and compliance with global standards.

Recombinant Pharmaceutical Products: Hepalink participates in the development and manufacture of cutting-edge recombinant pharmaceutical products, which are critical for advancing treatments in various medical fields. This includes work on non-viral vectors and intermediates for gene therapy, showcasing the company's commitment to innovation.

Naturally Derived Pharmaceutical Products: The emphasis on products derived from natural sources further highlights Hepalink’s dedication to exploring all facets of pharmaceutical development, ensuring they provide solutions that cater to diverse market needs and preferences.

Additional Services: Beyond direct product offerings, Hepalink enters the realm of property management, investment management and consulting, biopharmaceutical technology development and consulting, and even equity and venture investments. These activities demonstrate the company's adaptability and its strategic approach to leverage its pharmaceutical expertise into related areas, enhancing overall business resilience and growth.